BioSpace News Archive

Abivax SA (Euronext Paris: FR0012333284 - ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announces today its 2023 half-year financial results, as of June 30, 2023.

Adverum Biotechnologies, Inc., a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced that Adverum Biotechnologies will present at the following upcoming investor conferences.

DermTech, Inc. announced that DermTech’s Compensation Committee has granted an equity award to its new chief commercial officer, Mark Aguillard.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023, at 11:40 AM ET in New York City.

Riverside University Health System is proud to announce the implementation of FloPatch by Flosonics Medical. As a pioneer in adopting new, ground-breaking medical technology, Riverside is making a significant leap forward in healthcare innovation, particularly in the life-saving area of sepsis management.

Researchers at The University of Queensland are harnessing the latest sequencing technology developed by UK-based biotech Oxford Nanopore Technologies to analyse mRNA vaccines and therapies.

Pär Boman has declined re-election as Chairman of Essity’s Board of Directors. He will remain as Chairman of the Board until March 2024.

Jaguar Health, Inc. today announced that Magdalena Biosciences, Inc. successfully completed an import of coca leaf to a Filament facility (Psilo Scientific) in Canada.

CymaBay Therapeutics, Inc. today announced the initiation of AFFIRM, a randomized, placebo-controlled confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due to primary biliary cholangitis (PBC).

Eyenovia, Inc. today announced that Michael Rowe, CEO, will be participating in a panel discussion at the Cantor Global Healthcare Conference, which is taking place September 26-28, 2023, in New York.